Clindamycin · oral capsule
Antibiotic
OFF-LABELNot in the FDA label for this product
Toxoplasmic retinochoroiditis, by intravitreal injection
1 mg clindamycin with 400 micrograms dexamethasone intravitreally, 1 to 3 injections. This is a compounded intravitreal preparation and NOT this oral capsule, which cannot be injected. Oral clindamycin's own role is as an alternative agent, usually substituted for sulfadiazine in sulfa-allergic patients, and that use has no randomized evidence behind it.
RCT n=68 · not this oral form
Read the route before the result. A randomized trial compared intravitreal clindamycin with dexamethasone against classic therapy, which in that trial was 6 weeks of pyrimethamine and sulfadiazine plus prednisolone and contained no clindamycin. Across 68 patients the primary endpoint did not separate the arms: lesions reduced 57.0% against 58.4% (p=0.569), so the finding is that the injection is an acceptable alternative rather than a better one, and 34 patients per arm cannot exclude a real difference either way. Nothing here tests the oral capsule this card describes.
Contraindications
CLEOCIN HCl is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
75 mg, 150 mg, and 300 mg capsules, bottles of 100 for each strength
Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.
Warnings & Precautions
- Clostridioides difficile infection: CDI, reported with nearly all antibacterial agents, may range from mild diarrhea to fatal colitis. Reserve CLEOCIN HCl for serious infections where less toxic antimicrobial agents are inappropriate, not for nonbacterial infections like most upper respiratory tract infections. Consider CDI in any patient with diarrhea after antibacterial use, even over two months later. If CDI is suspected or confirmed, antibacterial drugs not directed against C. difficile may need to be stopped.
- Anaphylactic and Severe Hypersensitivity Reactions: Anaphylactic shock and anaphylactic reactions have been reported. Severe hypersensitivity reactions, including acute myocardial ischemia with or without myocardial infarction, and severe skin reactions such as TEN, DRESS, and SJS, some with fatal outcome, have been reported. If one occurs, discontinue treatment permanently and institute appropriate therapy. Ask about previous sensitivities to drugs and other allergens, and use caution in atopic individuals.
- Nephrotoxicity: Clindamycin is potentially nephrotoxic and cases with acute kidney injury have been reported. Consider monitoring of renal function, particularly in patients with pre-existing renal dysfunction or those taking concomitant nephrotoxic drugs. In case of acute kidney injury, discontinue CLEOCIN HCl when no other etiology is identified.
- Usage in meningitis: Clindamycin does not diffuse adequately into the cerebrospinal fluid, so the drug should not be used in the treatment of meningitis.
- Diarrhea: Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well, so monitor them carefully for change in bowel frequency. Prescribe with caution in individuals with a history of gastrointestinal disease, particularly colitis.
- Esophagitis and esophageal ulcer: Due to the risk of esophagitis and esophageal ulcer, ensure adherence with administration guidance (a full glass of water, and at least 30 minutes before lying down).
- Superinfections: CLEOCIN HCl occasionally results in overgrowth of nonsusceptible organisms, particularly yeasts. Should superinfections occur, take appropriate measures as indicated by the clinical situation.
- Prolongation of clindamycin half-life: In moderate to severe liver disease, prolongation of clindamycin half-life has been found. Dosage modification may not be necessary, but periodic liver enzyme determinations should be made when treating patients with severe liver disease.
- Tartrazine sensitivity: The 75 mg and 150 mg capsules contain FD&C yellow no. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Tartrazine sensitivity is frequently seen in patients who also have aspirin hypersensitivity.
- Drug-resistant bacteria: Prescribing CLEOCIN HCl in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
- Laboratory tests: During prolonged therapy, periodic liver and kidney function tests and blood counts should be performed.
- Neuromuscular blocking properties: Clindamycin may enhance the action of other neuromuscular blocking agents, so use it with caution in patients receiving such agents.
- Altered clindamycin plasma concentrations: Inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin, and inducers may reduce them. With strong CYP3A4 inhibitors, monitor for adverse reactions; with strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.
Common Side Effects
Generalized mild to moderate morbilliform-like (maculopapular) skin rashes are the most frequently reported adverse reactions. Vesiculobullous rashes and urticaria have been observed during drug therapy. Gastrointestinal reactions include abdominal pain, pseudomembranous colitis, Clostridioides difficile colitis, nausea, vomiting, and diarrhea, and the onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment. Esophagitis (including necrotizing esophagitis) and esophageal ulcer have been reported, particularly when taken in a lying position or with a small amount of water. An unpleasant or metallic taste has been reported after oral administration. Jaundice and abnormal liver function tests have been observed. Transient neutropenia (leukopenia) and eosinophilia have been reported, but no direct etiologic relationship to clindamycin could be made.
Pregnancy: In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.
Lactation: Limited published data based on breast milk sampling reports that clindamycin appears in human breast milk in the range of less than 0.5 to 3.8 mcg/mL. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibacterial drug-associated colitis.
When CLEOCIN HCl is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable.